The future we aim for
Tissue Culture Medium
Tissue culture business contributes to the development of medical care
Through the development, manufacture, and sale of cell culture media, our tissue culture business contributes to the advancement of life sciences, including regenerative medicine and the production of antibody drugs.
Technological innovations in serum-free media and chemically defined (CD) media are expected to improve the efficiency and safety of cell culture.
Additionally, by developing media specialized for culturing specific cells such as mesenchymal stem cells and immune cells, we will be able to address unmet medical needs.
As the regenerative medicine market expands, we believe we can play an important role in bringing hope to more patients.
Tissue culture
A liquid that mimics the interstitial fluid used to culture cells
Flow of cell therapy and regenerative medicine
Microbiological Medium
Microbiology business contributes to human health
The Microbiology Division develops, manufactures, and sells products that help identify microorganisms that cause infectious diseases and food contamination.
In order to visually confirm invisible microorganisms, we use technology to color substances derived from microorganisms and technology to grow the microorganisms themselves.
We contribute to human health through infectious disease/microbial testing in the medical field, quality testing in the pharmaceutical and cosmetics field, and pathogen testing in the food field.
Contract Cell Process
We will accelerate our growth by expanding free medical treatment in Japan and also considering overseas expansion.
The Cell Processing Department will accelerate growth through overseas expansion while building a solid position in the free medical treatment market.
We will actively invest in equipment to increase production capacity and expand our CPC (cell-processed products) business to overseas markets with high demand, such as Vietnam and Indonesia, in order to develop our business with a global perspective.
As overseas travel restrictions are eased, we will expand our cell processing facilities to meet the needs of an increasing number of inbound patients.
Through these efforts, we aim to open up the future of medicine and provide high-quality cell therapy to people around the world.